Latest cytarabine Stories

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments. George P. Tuszynski, a professor of neuroscience in Temple University's School of Medicine who discovered Angiocidin, will present the findings during the American Society of Hematology's national meeting in Atlanta on Dec. 9. AML causes certain white blood cells to stop maturing, resulting in their uncontrolled...

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy. In this study, higher rates of objective response (primary endpoint) and a trend for longer median event free...

RIDGEFIELD, Conn., Nov. 29, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54(th) American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga. Data include results from the Phase II portion of a Phase I/II study evaluating volasertib administered in addition to low-dose cytarabine (LDAC) compared to LDAC...

A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis (LCH) in bones. LCH is a disease that can affect the skin, mouth, ears, bones, brain, gastrointestinal system, liver, spleen, or bone marrow. In the study, appearing in the current issue of PLOS ONE, researchers reviewed health records for 58 adults with the disease and compared the effectiveness of three chemotherapy treatments –...

WHITE PLAINS, N.Y. and PRINCETON, N.J., July 2, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society® (LLS) and Celator Pharmaceuticals, Inc. today announced a significant expansion of their partnership to support clinical development and potential registration of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML). Under the new agreement, LLS will provide $5 million in funding,...

SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). Drs. John Pagel and Elihu Estey, from the University of Washington School of...

BEDFORD, Ohio, Feb. 16, 2012 /PRNewswire/ -- Bedford Laboratories(TM) announces a nationwide voluntary recall for the following three lots of Cytarabine for Injection, USP: Cytarabine for Injection, USP 1 gram per vial - NDC #55390-133-01 Lot 2066986 - Exp. Date March 31, 2014 Lot 2111675 - Exp. Date December 31, 2013 Lot 2131148 - Exp. Date May 31, 2014 (Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO ) This voluntary market recall is being conducted due to a...

WHITE PLAINS, N.Y., Feb. 14, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has been acutely aware of the dire shortage of drugs used to treat patients with cancer since the matter first emerged last fall. There have been a number of drugs on the shortage list that specifically impact patients with a blood cancer, and this week in particular, attention has turned to the limited supplies of Methotrexate, a drug used to treat children with acute lymphocytic leukemia as...

DALLAS, December 19, 2011 /PRNewswire/ -- The "Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in regions such as North America, Europe, and Japan. Browse market data tables and in-depth TOC on Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020). http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html...

National Phase III clinical trial will test histone deacetylase inhibitor with frontline therapy Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology. Results of the Phase II clinical trial of 75 patients set the stage for a national Phase III...